Next-generation sequencing outperforms Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) in endometrial cancer molecular classification
NGS surpassed ProMisE in EC molecular classification, offering precise stratification and prognostication. Our NGS platform has the potential to contribute to personalized treatment in EC.
Authors
- Miho Kawaida (ORCID: https://orcid.org/0000-0003-0353-4246)
- Wataru Yamagami (ORCID: https://orcid.org/0000-0003-3925-6057)
- Tatsuyuki Chiyoda (ORCID: https://orcid.org/0000-0002-8214-2242)
- Reika Takamatsu
- Takuma Yoshimura (ORCID: https://orcid.org/0000-0001-9919-1692)
- Eriko Aimono (ORCID: https://orcid.org/0000-0002-2749-654X)
- Hiroshi Nishihara (ORCID: https://orcid.org/0000-0002-5460-8703)
- Yohei Masugi (ORCID: https://orcid.org/0000-0002-6952-4043)
- Kohei Nakamura (ORCID: https://orcid.org/0000-0002-5162-7132)
- Kensuke Sakai (ORCID: https://orcid.org/0000-0002-1406-086X)
- Ryutaro Kawano
Institutions
- Tokai University (JP)
- Keio University (JP)
- Ito Hospital (JP)
- Keio University Hospital (JP)
Publication Details
- Journal
- BJC Reports
- Published
- 2025-05-20
- DOI
- https://doi.org/10.1038/s44276-025-00145-2
- Citations
- 4
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 8.23
Funders
- Japan Agency for Medical Research and Development
- Keio University
- Japan Society for the Promotion of Science